Description
Clopidogrel-Zentiva Coated Tablets 75 mg. №90
Ingredients
Active ingredient: Clopidogrel bisulfate. Inactive ingredients: microcrystalline cellulose, hydrogenated castor oil, hydroxypropyl cellulose, hypromellose, mannitol, titanium dioxide, talc, and more.
Mechanism of Action
Clopidogrel-Zentiva works by irreversibly inhibiting the P2Y12 adenosine diphosphate receptor on platelets, thereby preventing platelet aggregation and reducing the risk of thrombotic events.
Pharmacological Properties
The antiplatelet effect of Clopidogrel-Zentiva plays a crucial role in the management of cardiovascular diseases.
Indications for Use
Indicated for: Prevention of atherothrombotic events in patients suffering from acute coronary syndrome, recent myocardial infarction, ischemic stroke, or established peripheral arterial disease.
Contraindications
Do not use if: Hypersensitive to clopidogrel or any component of the formulation, active pathological bleeding such as peptic ulcer or intracranial hemorrhage.
Side Effects
Common side effects may include gastrointestinal discomfort, bruising, or bleeding. Consult a healthcare provider for a complete list of side effects.
Usage Instructions
Administration: Swallow the tablet whole with water. Do not crush or chew the tablet. The usual dose is one tablet daily, with or without food, or as directed by a healthcare professional.
Benefits Compared to Analogues
Compared to other antiplatelet agents, clopidogrel has shown similar efficacy in preventing cardiovascular events with a lower risk of gastrointestinal bleeding, making it a preferred choice in many clinical scenarios.
Suitable Patient Groups
Clopidogrel-Zentiva is suitable for adult patients and has been used in various age groups, including the elderly population, with appropriate monitoring for adverse effects.
Storage and Shelf Life
Store Clopidogrel-Zentiva in a cool, dry place away from direct sunlight. Check the expiration date on the packaging and do not use the product after the specified date.
Packaging Description
Clopidogrel-Zentiva comes in blister packs containing 90 coated tablets of 75 mg each. The packaging is designed to maintain the stability and integrity of the tablets.
Scientific Evidence
Clopidogrel-Zentiva has been extensively studied in various clinical trials to establish its efficacy in reducing cardiovascular events. Research published in the New England Journal of Medicine demonstrated that clopidogrel, in combination with aspirin, significantly reduced the risk of major cardiovascular events in patients with acute coronary syndrome.
